Overview
Zach Cochran is a partner in the Financial Restructuring group at Paul Hastings and is based in the firm’s New York and Atlanta offices.
Zach represents public and private companies and investors in a variety of capital markets transactions, with a focus on public and private offerings and liability management transactions involving all types of convertible, exchangeable and other equity-linked securities. Zach also regularly advises institutional investors regarding investments in public company securities.
Zach also has significant experience advising public companies and their boards of directors on general corporate, governance and disclosure matters. Zach represents companies and investors active in a variety of industries, including pharmaceuticals, medical devices, financial services and technology.
Education
- Boston University, J.D. (summa cum laude)
- University of Georgia, B.S. in Mathematics (summa cum laude, with highest honors)
Representations
- Convertible noteholders in a private negotiated exchange of outstanding convertible notes with Acorda Therapeutics
- Investors in structuring and negotiating investments in exchangeable senior notes and first lien exchangeable term loans issued by Gamida Cell
- Convertible noteholders in a private negotiated exchange of outstanding convertible notes for new convertible notes and warrants issued by Electra Battery Material Corporation
- Evolent Health in multiple private exchanges of its outstanding convertible notes, the issuance of its Series A convertible preferred stock to finance (in part) its acquisition of Magellan Specialty Health and a $402.5 million convertible notes offering
- Convertible noteholders in a private negotiated exchange of outstanding convertible notes for first lien term loans and warrants issued by Veritone
- Investors in structuring and negotiating convertible note investments in Nogin and Compusecure to finance (in part) the IPO of each issuer through de-SPAC transactions
- Investors in structuring and negotiating first lien convertible note investments in Reed’s
- Various institutional investors in structuring and negotiating investments in convertible senior notes issued by, among others, Akoustis, LumiraDx, RumbleOn and NantHealth
- EVO Payments in its $250 million “Up-C” IPO, multiple secondary offerings and a $150 million convertible preferred stock investment by Madison Dearborn
- SunTrust Banks in various securities offerings, including public offerings of common stock, preferred stock and senior notes
- National Australia Bank and Great Western Bancorp in connection with Great Western Bancorp’s IPO
- Piedmont Office Realty Trust in multiple offerings of senior notes (including green senior notes) and in its at-the-market forward sale program
- Various issuers, including Nivalis Therapeutics, Endochoice and Americold Realty Trust, in connection with their IPOs
Matters may have been handled prior to joining Paul Hastings.
Involvement
- American Bar Association